Page contentsPage contents Key facts Decision Key facts Active substance ramiprilIndapamide Therapeutic area Vascular disorders Decision number P/0466/2023 PIP number EMEA-003498-PIP01-23 Pharmaceutical form(s) Capsule, hard Condition(s) / indication(s) Treatment of hypertension Route(s) of administration Oral use Contact for public enquiries Egis Pharmaceuticals Plc. E-mail: registry@regis.hu Tel. +36 18032414 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 01/12/2023 Compliance check done No Decision P/0466/2023 : EMA decision of 1 December 2023 on the granting of a product-specific waiver for ramipril / indapamide (EMEA-003498-PIP01-23)Adopted Reference Number: EMA/501922/2008 English (EN) (181.43 KB - PDF)First published: 07/03/2025 View Share this page